Cargando…
GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy
Interest in gene-based therapies for neurodevelopmental disorders is increasing exponentially, driven by the rise in recognition of underlying genetic etiology, progress in genomic technology, and recent proof of concept in several disorders. The current prioritization of one genetic disorder over a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478871/ https://www.ncbi.nlm.nih.gov/pubmed/36156879 http://dx.doi.org/10.1016/j.omtm.2022.08.007 |
_version_ | 1784790670936899584 |
---|---|
author | Chopra, Maya Modi, Meera E. Dies, Kira A. Chamberlin, Nancy L. Buttermore, Elizabeth D. Brewster, Stephanie Jo Prock, Lisa Sahin, Mustafa |
author_facet | Chopra, Maya Modi, Meera E. Dies, Kira A. Chamberlin, Nancy L. Buttermore, Elizabeth D. Brewster, Stephanie Jo Prock, Lisa Sahin, Mustafa |
author_sort | Chopra, Maya |
collection | PubMed |
description | Interest in gene-based therapies for neurodevelopmental disorders is increasing exponentially, driven by the rise in recognition of underlying genetic etiology, progress in genomic technology, and recent proof of concept in several disorders. The current prioritization of one genetic disorder over another for development of therapies is driven by competing interests of pharmaceutical companies, advocacy groups, and academic scientists. Although these are all valid perspectives, a consolidated framework will facilitate more efficient and rational gene therapy development. Here we outline features of Mendelian neurodevelopmental disorders that warrant consideration when determining suitability for gene therapy. These features fit into four broad domains: genetics, preclinical validation, clinical considerations, and ethics. We propose a simple mnemonic, GENE TARGET, to remember these features and illustrate how they could be scored using a preliminary scoring rubric. In this suggested rubric, for a given disorder, scores for each feature may be added up to a composite GENE TARGET suitability (GTS) score. In addition to proposing a systematic method to evaluate and compare disorders, our framework helps identify gaps in the translational pipeline for a given disorder, which can inform prioritization of future research efforts. |
format | Online Article Text |
id | pubmed-9478871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-94788712022-09-22 GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy Chopra, Maya Modi, Meera E. Dies, Kira A. Chamberlin, Nancy L. Buttermore, Elizabeth D. Brewster, Stephanie Jo Prock, Lisa Sahin, Mustafa Mol Ther Methods Clin Dev Review Interest in gene-based therapies for neurodevelopmental disorders is increasing exponentially, driven by the rise in recognition of underlying genetic etiology, progress in genomic technology, and recent proof of concept in several disorders. The current prioritization of one genetic disorder over another for development of therapies is driven by competing interests of pharmaceutical companies, advocacy groups, and academic scientists. Although these are all valid perspectives, a consolidated framework will facilitate more efficient and rational gene therapy development. Here we outline features of Mendelian neurodevelopmental disorders that warrant consideration when determining suitability for gene therapy. These features fit into four broad domains: genetics, preclinical validation, clinical considerations, and ethics. We propose a simple mnemonic, GENE TARGET, to remember these features and illustrate how they could be scored using a preliminary scoring rubric. In this suggested rubric, for a given disorder, scores for each feature may be added up to a composite GENE TARGET suitability (GTS) score. In addition to proposing a systematic method to evaluate and compare disorders, our framework helps identify gaps in the translational pipeline for a given disorder, which can inform prioritization of future research efforts. American Society of Gene & Cell Therapy 2022-08-29 /pmc/articles/PMC9478871/ /pubmed/36156879 http://dx.doi.org/10.1016/j.omtm.2022.08.007 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Chopra, Maya Modi, Meera E. Dies, Kira A. Chamberlin, Nancy L. Buttermore, Elizabeth D. Brewster, Stephanie Jo Prock, Lisa Sahin, Mustafa GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy |
title | GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy |
title_full | GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy |
title_fullStr | GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy |
title_full_unstemmed | GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy |
title_short | GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy |
title_sort | gene target: a framework for evaluating mendelian neurodevelopmental disorders for gene therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478871/ https://www.ncbi.nlm.nih.gov/pubmed/36156879 http://dx.doi.org/10.1016/j.omtm.2022.08.007 |
work_keys_str_mv | AT chopramaya genetargetaframeworkforevaluatingmendelianneurodevelopmentaldisordersforgenetherapy AT modimeerae genetargetaframeworkforevaluatingmendelianneurodevelopmentaldisordersforgenetherapy AT dieskiraa genetargetaframeworkforevaluatingmendelianneurodevelopmentaldisordersforgenetherapy AT chamberlinnancyl genetargetaframeworkforevaluatingmendelianneurodevelopmentaldisordersforgenetherapy AT buttermoreelizabethd genetargetaframeworkforevaluatingmendelianneurodevelopmentaldisordersforgenetherapy AT brewsterstephaniejo genetargetaframeworkforevaluatingmendelianneurodevelopmentaldisordersforgenetherapy AT procklisa genetargetaframeworkforevaluatingmendelianneurodevelopmentaldisordersforgenetherapy AT sahinmustafa genetargetaframeworkforevaluatingmendelianneurodevelopmentaldisordersforgenetherapy |